Forxiga® (dapagliflozin): Risk of Diabetic Ketoacidosis During Treatment With Sodium Glucose Co-transporter 2 (SGLT2)Inhibitor - Dapagliflozin

Kadar pengguna: 2 / 5

bintang aktifbintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif

Date: 17 August 2015



A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals that serious cases of diabetic ketoacidosis (DKA) have been reported in patients on SGLT2 inhibitor treatment for type 2 diabetes. A number of these cases reported patients presenting with only moderately increased blood glucose levels. Such atypical presentation of DKA could delay diagnosis and treatment. Patients on SGLT2 inhibitors who present with symptoms of acidosis should be tested for ketones, to ensure quick diagnosis and management. Please refer to the DHPC for further information.

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400



Image   Image   Image   Image  


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Jumaat 22 September 2023, 14:42:56.
© Copyright 2023 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA